A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting now · Phase 1
Conditions studied: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
In brief
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Key facts
- Study ID
- NCT05131022
- Run by
- Nurix Therapeutics, Inc.
- People needed
- 572
- Starts
- 2022-04-13
- Expected to finish
- 2028-01-01
- Last updated by the study team
- 2026-07-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- IRCCS Ospedale San Raffaele — Milan, Italy (enrolling)
- Colorado Blood Cancer Institute — Denver, Colorado, United States (enrolling)
- IRCCS Ospedale San Raffaele - Università Vita-Salute San Raffaele di Milano — Milan, Italy (enrolling)
- City of Hope — Duarte, California, United States (enrolling)
- Florida Cancer Specialists — Sarasota, Florida, United States (enrolling)
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States (enrolling)
- Yale Cancer Center — New Haven, Connecticut, United States (enrolling)
- National Institute of Health — Bethesda, Maryland, United States (enrolling)
- University of Miami — Miami, Florida, United States (enrolling)
- University of California, San Francisco — San Francisco, California, United States (enrolling)
- Duke University Medical Center — Durham, North Carolina, United States (enrolling)
- University of Cincinnati Medical Center — Cincinnati, Ohio, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Northwestern University — Chicago, Illinois, United States (enrolling)
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
- CHU Angers — Angers, France (enrolling)
- Hôpital Avicenne — Bobigny, France (enrolling)
- CHU de Nantes — Nantes, France (enrolling)
- CHU Bordeaux — Pessac, France (enrolling)
- CHU de Poitiers — Poitiers, France (enrolling)
- Institut Curie-Site Saint-Cloud — Saint-Cloud, France (enrolling)
- CHRU de Nancy — Vandœuvre-lès-Nancy, France (enrolling)
- Fondazione Policlinico Universitario A. Gemelli IRCCS — Rome, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.